organic sulfate salt - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	organic sulfate salt	go back to main search page
Accession:	CHEBI:51337	browse the term
Synonyms:	related_synonym:	organic sulfate salts

show annotations for term's descendants Sort by:
Rat (220) Mouse (218) Human (226) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (220)

5-methylphenazinium methyl sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

glucose-6-phosphate dehydrogenase

increases activity

Methylphenazonium Methosulfate results in increased activity of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

phosphogluconate dehydrogenase

increases activity

Methylphenazonium Methosulfate results in increased activity of PGD protein

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

atazanavir sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity
multiple interactions

Atazanavir Sulfate results in decreased activity of ABCB11 protein
Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases transport
multiple interactions

ABCB1 protein results in increased transport of Atazanavir Sulfate
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA

PMID:29859254 PMID:33819548

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 2

decreases expression

Atazanavir Sulfate results in decreased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

decreases expression

Atazanavir Sulfate results in decreased expression of ABCC3 mRNA

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

adhesion G protein-coupled receptor G1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 4 (class II), pi polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

alcohol dehydrogenase 6 (class V)

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA

NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534

G

aldo-keto reductase family 1, member D1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

aldo-keto reductase family 7 member A3

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of AKR7A3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

albumin

affects binding
multiple interactions

Atazanavir Sulfate binds to ALB protein
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA

PMID:15814459 PMID:16336266 PMID:33819548

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, placental

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

adenosine monophosphate deaminase 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

apolipoprotein A1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

activating transcription factor 4

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA
Atazanavir Sulfate results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA
Atazanavir Sulfate results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 7

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of ATG7 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATPase phospholipid transporting 8B1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

Bcl2-like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

catalase

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CAT mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

increases expression

Atazanavir Sulfate results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

increases expression

Atazanavir Sulfate results in increased expression of CCL3 protein

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

chitinase 3 like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

colony stimulating factor 1

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA
Atazanavir Sulfate results in increased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

catenin beta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cortactin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

CYLD lysine 63 deubiquitinase

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of CYLD mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 3

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CYP2B6 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CYP3A4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of CYP7A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA
Atazanavir Sulfate results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA
Atazanavir Sulfate results in increased expression of DNAJC10 mRNA

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

DnaJ heat shock protein family (Hsp40) member C12

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA

NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521

G

DnaJ heat shock protein family (Hsp40) member C9

increases expression

Atazanavir Sulfate results in increased expression of DNAJC9 mRNA

NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118

G

epoxide hydrolase 1

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA
Atazanavir Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

FKBP prolyl isomerase 5

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA
Atazanavir Sulfate results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

flavin containing dimethylaniline monoxygenase 1

decreases expression

Atazanavir Sulfate results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

FOS like 1, AP-1 transcription factor subunit

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA
Atazanavir Sulfate results in increased expression of FOSL1 mRNA

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

gamma-glutamyltransferase 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

gap junction protein, beta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA

NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925

G

glycerol kinase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA

NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA

NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932

G

glutathione peroxidase 2

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA
Atazanavir Sulfate results in decreased expression of GPX2 mRNA

PMID:32152650 PMID:33819548

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione S-transferase alpha 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of GSTA1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 4

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA

NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323

G

2-hydroxyacyl-CoA lyase 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA

NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027

G

hepatocyte growth factor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

heme oxygenase 1

multiple interactions
increases expression

Atazanavir Sulfate promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA]
Atazanavir Sulfate results in increased expression of HMOX1 mRNA; Atazanavir Sulfate results in increased expression of HMOX1 protein

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hemopexin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA

NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328

G

heat shock protein family A (Hsp70) member 5

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of HSPA5 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

intercellular adhesion molecule 1

increases expression

Atazanavir Sulfate results in increased expression of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

immediate early response 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA

NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583

G

interferon, alpha-inducible protein 27

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA

NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294

G

insulin-like growth factor binding protein 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 6

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunD proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA

NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799

G

kynureninase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA

NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488

G

lipopolysaccharide binding protein

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

low density lipoprotein receptor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lipase C, hepatic type

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lymphocyte antigen 96

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA

NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386

G

MAF bZIP transcription factor F

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of MAFF mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA
Atazanavir Sulfate results in increased expression of MAP1LC3B mRNA

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase 6

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA
Atazanavir Sulfate results in decreased expression of MAP2K6 mRNA

NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293

G

MAPK activated protein kinase 3

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of MAPKAPK3 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA

NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568

G

mixed lineage kinase domain like pseudokinase

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA
Atazanavir Sulfate results in increased expression of MLKL mRNA

PMID:32152650 PMID:33819548

NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502

G

methylmalonyl-CoA mutase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA

NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046

G

microsomal triglyceride transfer protein

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

nuclear transcription factor, X-box binding-like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA

NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of NR1H4 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of NR1I2 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA
Atazanavir Sulfate results in decreased expression of NR1I3 mRNA

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

phenylalanine hydroxylase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of PIK3C2G mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA

NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544

G

phosphoinositide-3-kinase regulatory subunit 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of PIK3R1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

paraoxonase 1

decreases activity

Atazanavir Sulfate results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

peroxisome proliferator activated receptor alpha

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 1, regulatory subunit 3C

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA

NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961

G

RAS like proto-oncogene A

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA

NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063

G

receptor accessory protein 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA

NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

sterol carrier protein 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA

NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287

G

syndecan 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA

NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081

G

serpin family E member 1

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of SERPINE1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SH3 domain -containing GRB2-like endophilin B1

increases expression
multiple interactions

Atazanavir Sulfate results in increased expression of SH3GLB1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA

NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784

G

solute carrier family 10 member 1

multiple interactions
decreases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA
Atazanavir Sulfate results in decreased expression of SLC10A1 mRNA

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 17 member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 22 member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 51 member A

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SLC51 subunit beta

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

superoxide dismutase 2

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA
Atazanavir Sulfate results in increased expression of SOD2 mRNA

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sortilin related receptor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA

NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513

G

sequestosome 1

multiple interactions
increases expression

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA
Atazanavir Sulfate results in increased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal recognition particle 72

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA

NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729

G

sulfotransferase family 2A member 1

decreases expression
multiple interactions

Atazanavir Sulfate results in decreased expression of SULT2A1 mRNA
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

tissue factor pathway inhibitor

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

toll-like receptor 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

TNF receptor superfamily member 10b

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA

NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467

G

TNF superfamily member 10

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA

NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135

G

TNF superfamily member 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

cefoselis sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier family 22 member 6

multiple interactions

cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid]

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

G

solute carrier family 22 member 8

increases uptake
multiple interactions

SLC22A8 protein results in increased uptake of cefoselis
cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate]

NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450

erythromycin estolate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases expression
decreases activity

Erythromycin Estolate results in decreased expression of ABCB11 mRNA
Erythromycin Estolate results in decreased activity of ABCB11 protein

PMID:17522070 PMID:20829430 PMID:23956101 PMID:28437613

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression

Erythromycin Estolate results in increased expression of ABCB1 mRNA; Erythromycin Estolate results in increased expression of ABCB1A mRNA

PMID:17522070 PMID:24412560

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 3

increases expression

Erythromycin Estolate results in increased expression of ABCC3 mRNA

PMID:17522070 PMID:24412560

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 5

increases expression

Erythromycin Estolate results in increased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

increases expression

Erythromycin Estolate results in increased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acyl-CoA dehydrogenase medium chain

decreases expression

Erythromycin Estolate results in decreased expression of ACADM mRNA

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

ATP citrate lyase

decreases expression

Erythromycin Estolate results in decreased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA synthetase long-chain family member 1

decreases expression

Erythromycin Estolate results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

aldehyde dehydrogenase 1 family, member A1

increases expression

Erythromycin Estolate results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 3 family, member A2

decreases expression

Erythromycin Estolate results in decreased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

apurinic/apyrimidinic endodeoxyribonuclease 1

decreases expression

Erythromycin Estolate results in decreased expression of APEX1 mRNA

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

assembly factor for spindle microtubules

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of ASPM mRNA
Erythromycin Estolate results in increased expression of ASPM mRNA

NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755

G

aurora kinase B

increases expression
decreases expression

Erythromycin Estolate results in increased expression of AURKB mRNA
Erythromycin Estolate results in decreased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

BCL2 associated X, apoptosis regulator

decreases expression

Erythromycin Estolate results in decreased expression of BAX mRNA

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression

Erythromycin Estolate results in increased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BTG anti-proliferation factor 2

increases expression

Erythromycin Estolate results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

calcium voltage-gated channel subunit alpha1 I

decreases expression

Erythromycin Estolate results in decreased expression of CACNA1I mRNA

NCBI chr 7:111,835,996...111,947,418
Ensembl chr 7:111,836,012...111,944,688

G

calumenin

increases expression

Erythromycin Estolate results in increased expression of CALU mRNA

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

carbonic anhydrase 1

decreases expression

Erythromycin Estolate results in decreased expression of CAR1 mRNA

NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208

G

catalase

decreases expression

Erythromycin Estolate results in decreased expression of CAT mRNA

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 2

decreases expression

Erythromycin Estolate results in decreased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cyclin A2

increases expression
decreases expression

Erythromycin Estolate results in increased expression of CCNA2 mRNA
Erythromycin Estolate results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of CCNB1 mRNA
Erythromycin Estolate results in increased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cell division cycle associated 3

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of CDCA3 mRNA
Erythromycin Estolate results in increased expression of CDCA3 mRNA

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cyclin-dependent kinase 1

increases expression
decreases expression

Erythromycin Estolate results in increased expression of CDK1 mRNA
Erythromycin Estolate results in decreased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

CEA cell adhesion molecule 1

decreases expression

Erythromycin Estolate results in decreased expression of CEACAM1 mRNA

NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992

G

centromere protein W

increases expression
decreases expression

Erythromycin Estolate results in increased expression of CENPW mRNA
Erythromycin Estolate results in decreased expression of CENPW mRNA

NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464

G

carboxylesterase 2H

increases expression

Erythromycin Estolate results in increased expression of CES2 mRNA

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

chromodomain helicase DNA binding protein 2

increases expression

Erythromycin Estolate results in increased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

cathepsin L

increases expression

Erythromycin Estolate results in increased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cytochrome b5 reductase 3

decreases expression

Erythromycin Estolate results in decreased expression of CYB5R3 mRNA

NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases expression

Erythromycin Estolate results in increased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 2, subfamily d, polypeptide 3

decreases expression

Erythromycin Estolate results in decreased expression of CYP2D3 mRNA

NCBI chr 7:113,917,711...113,922,068
Ensembl chr 7:113,908,947...113,922,084

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

Erythromycin Estolate results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

Erythromycin Estolate results in increased expression of CYP3A9 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 8 subfamily B member 1

increases expression

Erythromycin Estolate results in increased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

increases expression

Erythromycin Estolate results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

deoxyuridine triphosphatase

increases expression

Erythromycin Estolate results in increased expression of DUT mRNA

NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771

G

epithelial cell transforming 2

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of ECT2 mRNA
Erythromycin Estolate results in increased expression of ECT2 mRNA

NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911

G

fatty acid binding protein 1

increases expression

Erythromycin Estolate results in increased expression of FABP1 mRNA

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid desaturase 1

decreases expression

Erythromycin Estolate results in decreased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

FAM111 trypsin like peptidase A

increases expression
decreases expression

Erythromycin Estolate results in increased expression of FAM111A mRNA
Erythromycin Estolate results in decreased expression of FAM111A mRNA

NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547

G

fatty acid synthase

decreases expression

Erythromycin Estolate results in decreased expression of FASN mRNA

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibrinogen alpha chain

increases expression

Erythromycin Estolate results in increased expression of FGA mRNA

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

fibrinogen beta chain

increases expression

Erythromycin Estolate results in increased expression of FGB mRNA

NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979

G

flavin containing dimethylaniline monoxygenase 1

decreases expression

Erythromycin Estolate results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

Erythromycin Estolate results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Erythromycin Estolate results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glucokinase

decreases expression

Erythromycin Estolate results in decreased expression of GCK mRNA

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

glutathione peroxidase 1

decreases expression

Erythromycin Estolate results in decreased expression of GPX1 mRNA

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glutathione peroxidase 2

increases expression

Erythromycin Estolate results in increased expression of GPX2 mRNA

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione S-transferase, mu 5

decreases expression

Erythromycin Estolate results in decreased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

3-hydroxyisobutyrate dehydrogenase

decreases expression

Erythromycin Estolate results in decreased expression of HIBADH mRNA

NCBI chr 4:81,649,180...81,747,244
Ensembl chr 4:81,649,175...81,780,617

G

hyaluronan-mediated motility receptor

increases expression
decreases expression

Erythromycin Estolate results in increased expression of HMMR mRNA
Erythromycin Estolate results in decreased expression of HMMR mRNA

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

insulin-like growth factor 2 receptor

increases expression

Erythromycin Estolate results in increased expression of IGF2R mRNA

NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501

G

insulin-like growth factor binding protein 1

increases expression

Erythromycin Estolate results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 2

increases expression

Erythromycin Estolate results in increased expression of IGFBP2 mRNA

NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937

G

inositol hexakisphosphate kinase 2

decreases expression

Erythromycin Estolate results in decreased expression of IP6K2 mRNA

NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166

G

ISY1 splicing factor homolog

increases expression

Erythromycin Estolate results in increased expression of ISY1 mRNA

NCBI chr 4:120,276,535...120,297,227
Ensembl chr 4:120,276,292...120,297,188

G

kinesin family member 20B

increases expression
decreases expression

Erythromycin Estolate results in increased expression of KIF20B mRNA
Erythromycin Estolate results in decreased expression of KIF20B mRNA

NCBI chr 1:232,428,293...232,483,798
Ensembl chr 1:232,428,371...232,483,787

G

kinesin family member 23

increases expression
decreases expression

Erythromycin Estolate results in increased expression of KIF23 mRNA
Erythromycin Estolate results in decreased expression of KIF23 mRNA

NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072

G

kinesin family member 2C

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of KIF2C mRNA
Erythromycin Estolate results in increased expression of KIF2C mRNA

NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637

G

keratin 18

increases expression

Erythromycin Estolate results in increased expression of KRT18 mRNA

NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
Ensembl chr10:133,157,475...133,161,166

G

lipopolysaccharide binding protein

increases expression

Erythromycin Estolate results in increased expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

galectin 3

increases expression

Erythromycin Estolate results in increased expression of LGALS3 mRNA

NCBI chr15:20,620,083...20,632,019
Ensembl chr15:20,607,692...20,632,025

G

lipase C, hepatic type

decreases expression

Erythromycin Estolate results in decreased expression of LIPC mRNA

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

lipin 1

decreases expression

Erythromycin Estolate results in decreased expression of LPIN1 mRNA

NCBI chr 6:39,309,198...39,417,034
Ensembl chr 6:39,312,748...39,417,097

G

lipoprotein lipase

increases expression

Erythromycin Estolate results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

monoamine oxidase B

decreases expression

Erythromycin Estolate results in decreased expression of MAOB mRNA

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

microRNA 16

increases expression

Erythromycin Estolate results in increased expression of MIR16 mRNA

NCBI chr 2:153,245,349...153,245,443
Ensembl chr 2:153,245,349...153,245,443

G

MYC proto-oncogene, bHLH transcription factor

increases expression
decreases expression

Erythromycin Estolate results in increased expression of MYC mRNA
Erythromycin Estolate results in decreased expression of MYC mRNA

PMID:17522070 PMID:24412560

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

non-SMC condensin I complex, subunit H

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of NCAPH mRNA
Erythromycin Estolate results in increased expression of NCAPH mRNA

NCBI chr 3:114,371,937...114,399,178
Ensembl chr 3:114,371,941...114,399,180

G

NFKB inhibitor beta

decreases expression

Erythromycin Estolate results in decreased expression of NFKBIB mRNA

NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862

G

nocturnin

decreases expression

Erythromycin Estolate results in decreased expression of NOCT mRNA

NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:135,271,189...135,291,400

G

nucleolar and spindle associated protein 1

increases expression
decreases expression

Erythromycin Estolate results in increased expression of NUSAP1 mRNA
Erythromycin Estolate results in decreased expression of NUSAP1 mRNA

NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624

G

alpha-2u globulin PGCL4

decreases expression

Erythromycin Estolate results in decreased expression of OBP3 mRNA

NCBI chr 5:74,842,316...74,845,858
Ensembl chr 5:74,842,316...74,845,757

G

ornithine transcarbamylase

decreases expression

Erythromycin Estolate results in decreased expression of OTC mRNA

NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918

G

PCNA clamp associated factor

increases expression
decreases expression

Erythromycin Estolate results in increased expression of PCLAF mRNA
Erythromycin Estolate results in decreased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1

decreases expression

Erythromycin Estolate results in decreased expression of PCMTD1 mRNA

NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899

G

pyruvate dehydrogenase kinase 4

decreases expression

Erythromycin Estolate results in decreased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

period circadian regulator 1

decreases expression

Erythromycin Estolate results in decreased expression of PER1 mRNA

NCBI chr10:53,800,126...53,814,963
Ensembl chr10:53,805,535...53,814,431

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3

decreases expression

Erythromycin Estolate results in decreased expression of PFKFB3 mRNA

NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125

G

pyruvate kinase L/R

decreases expression

Erythromycin Estolate results in decreased expression of PKLR mRNA

NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870

G

glycogen phosphorylase L

decreases expression

Erythromycin Estolate results in decreased expression of PYGL mRNA

NCBI chr 6:88,697,598...88,740,260
Ensembl chr 6:88,697,593...88,740,310

G

RAD51 recombinase

increases expression
decreases expression

Erythromycin Estolate results in increased expression of RAD51 mRNA
Erythromycin Estolate results in decreased expression of RAD51 mRNA

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

ribonucleotide reductase regulatory subunit M2

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of RRM2 mRNA
Erythromycin Estolate results in increased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

S100 calcium binding protein A8

increases expression

Erythromycin Estolate results in increased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100 calcium binding protein A9

increases expression

Erythromycin Estolate results in increased expression of S100A9 mRNA

NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230

G

serpin family A member 7

increases expression

Erythromycin Estolate results in increased expression of SERPINA7 mRNA

NCBI chr X:102,663,242...102,722,319
Ensembl chr X:102,663,405...102,669,040

G

SERTA domain containing 3

increases expression

Erythromycin Estolate results in increased expression of SERTAD3 mRNA

NCBI chr 1:82,763,535...82,767,271
Ensembl chr 1:82,763,149...82,769,001

G

SHC binding and spindle associated 1

decreases expression
increases expression

Erythromycin Estolate results in decreased expression of SHCBP1 mRNA
Erythromycin Estolate results in increased expression of SHCBP1 mRNA

NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844

G

solute carrier family 38, member 2

decreases expression

Erythromycin Estolate results in decreased expression of SLC38A2 mRNA

NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436

G

solute carrier organic anion transporter family, member 1a4

increases expression

Erythromycin Estolate results in increased expression of SLCO1A4 mRNA

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

decreases expression

Erythromycin Estolate results in decreased expression of SLCO1B2 mRNA

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

SPC25 component of NDC80 kinetochore complex

increases expression
decreases expression

Erythromycin Estolate results in increased expression of SPC25 mRNA
Erythromycin Estolate results in decreased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

spindlin family member 2B

decreases expression

Erythromycin Estolate results in decreased expression of SPIN2B mRNA

NCBI chr X:17,190,573...17,192,351
Ensembl chr X:17,180,474...17,192,351

G

serine peptidase inhibitor, Kazal type 1

increases expression

Erythromycin Estolate results in increased expression of SPINK1 mRNA

NCBI chr18:35,870,723...35,882,693
Ensembl chr18:35,824,550...35,882,642

G

sterol regulatory element binding transcription factor 1

decreases expression

Erythromycin Estolate results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 3

increases expression

Erythromycin Estolate results in increased expression of STAT3 mRNA

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

serine/threonine/tyrosine interacting-like 1

increases expression

Erythromycin Estolate results in increased expression of STYXL1 mRNA

NCBI chr12:20,907,410...20,940,232
Ensembl chr12:20,907,435...20,939,752

G

SGT1 homolog, MIS12 kinetochore complex assembly cochaperone

increases expression

Erythromycin Estolate results in increased expression of SUGT1 mRNA

NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150

G

transforming growth factor, beta 3

decreases expression

Erythromycin Estolate results in decreased expression of TGFB3 mRNA

NCBI chr 6:105,704,058...105,726,661
Ensembl chr 6:105,704,236...105,726,564

G

thyroid hormone responsive

decreases expression

Erythromycin Estolate results in decreased expression of THRSP mRNA

NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075

G

TIMP metallopeptidase inhibitor 1

increases expression

Erythromycin Estolate results in increased expression of TIMP1 mRNA

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

transmembrane and coiled-coil domain family 1

decreases expression

Erythromycin Estolate results in decreased expression of TMCC1 mRNA

NCBI chr 4:149,069,252...149,239,585
Ensembl chr 4:149,069,260...149,239,620

G

TNF alpha induced protein 3

decreases expression

Erythromycin Estolate results in decreased expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 1A

increases expression

Erythromycin Estolate results in increased expression of TNFRSF1A mRNA

NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591

G

tumor protein p53

decreases expression

Erythromycin Estolate results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TSC22 domain family, member 3

decreases expression

Erythromycin Estolate results in decreased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

transthyretin

decreases expression

Erythromycin Estolate results in decreased expression of TTR mRNA

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:11,943,789...11,951,008

G

thioredoxin reductase 1

decreases expression

Erythromycin Estolate results in decreased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

UDP glucuronosyltransferase family 2 member A1

increases expression

Erythromycin Estolate results in increased expression of UGT2A1 mRNA

NCBI chr14:20,521,018...20,545,934
Ensembl chr14:20,517,951...20,545,531

G

zinc finger CCCH type containing 13

increases expression

Erythromycin Estolate results in increased expression of ZC3H13 mRNA

NCBI chr15:50,607,335...50,671,802
Ensembl chr15:50,607,380...50,671,802

G

zinc finger protein 354A

decreases expression

Erythromycin Estolate results in decreased expression of ZFP354A mRNA

NCBI chr10:35,396,242...35,408,069
Ensembl chr10:35,396,231...35,408,068

G

zinc finger protein 574

increases expression

Erythromycin Estolate results in increased expression of ZFP574 mRNA

NCBI chr 1:80,667,984...80,678,257
Ensembl chr 1:80,664,259...80,679,427

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19899
chemical entity	19897
molecular entity	19897
ion	17101
anion	16657
salt	16302
organic salt	3331
organic sulfate salt	220
2,5-diaminotoluene sulfate	0
4-methylaminophenol sulfate	0
L-canavanine sulfate	0
amphetamine sulfate +	0
atazanavir sulfate	117
debrisoquin sulfate	0
ethyl nile blue A	0
guanadrel sulfate	0
guanethidine monosulfate +	0
guanethidine sulfate	0
organoammonium sulfate salt +	119
quinine sulfate +	0
vincristine sulfate	0
vorapaxar sulfate	0
Path 2
Term	Annotations
CHEBI ontology	19899
subatomic particle	19897
composite particle	19897
hadron	19897
baryon	19897
nucleon	19897
atomic nucleus	19897
atom	19897
main group element atom	19835
p-block element atom	19835
chalcogen	19586
oxygen atom	19558
oxygen molecular entity	19558
hydroxides	19366
oxoacid	18804
chalcogen oxoacid	13804
sulfur oxoacid	13592
sulfuric acid	8255
sulfuric acid derivative	8255
sulfates	8250
sulfate salt	7139
organic sulfate salt	220
2,5-diaminotoluene sulfate	0
4-methylaminophenol sulfate	0
L-canavanine sulfate	0
amphetamine sulfate +	0
atazanavir sulfate	117
debrisoquin sulfate	0
ethyl nile blue A	0
guanadrel sulfate	0
guanethidine monosulfate +	0
guanethidine sulfate	0
organoammonium sulfate salt +	119
quinine sulfate +	0
vincristine sulfate	0
vorapaxar sulfate	0

paths to the root